Tesamorelin
Egrifta
Mechanism
GHRH analog that specifically targets visceral adipose tissue (VAT) and stimulates growth hormone release.
Half-Life
30-40 minutes
Administration
Technical Protocol
Tesamorelin Guide
Tesamorelin is FDA-approved for the treatment of HIV-associated lipodystrophy.
Peer-Reviewed Citations
Tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation
Falutz J, et al. • N Engl J Med (2007)
Access ResearchFrequently Asked Questions
What is Tesamorelin?
The most potent GHRH analog for visceral fat reduction.
How does Tesamorelin work?
GHRH analog that specifically targets visceral adipose tissue (VAT) and stimulates growth hormone release.
What is the typical dosage of Tesamorelin in research?
The typical research dosage of Tesamorelin is 2 mg (range: 1-2 mg daily). Common administration routes include Subcutaneous.
How should Tesamorelin be stored?
Store at 2-8°C, protect from light
Source Tesamorelin for Your Research
Third-party tested, EU-shipped, certificate of analysis included. High-purity Tesamorelin available from our verified research partner.
Shop TesamorelinRelated Hormonal Peptides
Ipamorelin
A potent and selective growth hormone secretagogue that stimulates growth hormone release.
hormonalCJC-1295 (No DAC)
A modified version of GHRH 1-29, designed to stimulate growth hormone release.
hormonalKisspeptin-10
A key regulator of the reproductive axis.
hormonalOxytocin
The hormone of social connection and maternal bonding.